BR112019012343A2 - anticorpos il-11ra - Google Patents
anticorpos il-11raInfo
- Publication number
- BR112019012343A2 BR112019012343A2 BR112019012343A BR112019012343A BR112019012343A2 BR 112019012343 A2 BR112019012343 A2 BR 112019012343A2 BR 112019012343 A BR112019012343 A BR 112019012343A BR 112019012343 A BR112019012343 A BR 112019012343A BR 112019012343 A2 BR112019012343 A2 BR 112019012343A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- disclosed
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5431—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1621439.7A GB201621439D0 (en) | 2016-12-16 | 2016-12-16 | IL-11Ra Antibodies |
| PCT/EP2017/083043 WO2018109170A2 (en) | 2016-12-16 | 2017-12-15 | Il-11ra antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019012343A2 true BR112019012343A2 (pt) | 2019-11-26 |
Family
ID=58284610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019012343A BR112019012343A2 (pt) | 2016-12-16 | 2017-12-15 | anticorpos il-11ra |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180186872A1 (enExample) |
| EP (1) | EP3555135B1 (enExample) |
| JP (1) | JP7175271B2 (enExample) |
| KR (1) | KR20190111924A (enExample) |
| CN (1) | CN110337447B (enExample) |
| AU (1) | AU2017378107A1 (enExample) |
| BR (1) | BR112019012343A2 (enExample) |
| CA (1) | CA3046848A1 (enExample) |
| GB (1) | GB201621439D0 (enExample) |
| MX (1) | MX2019007021A (enExample) |
| TW (1) | TW201829465A (enExample) |
| WO (1) | WO2018109170A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| KR20190096390A (ko) | 2016-12-16 | 2019-08-19 | 싱가포르 헬스 서비시즈 피티이 엘티디 | Il-11 항체 |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| KR20210138579A (ko) | 2019-01-21 | 2021-11-19 | 싱가포르 헬스 서비시즈 피티이 엘티디 | 간독성의 치료 |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| PH12021552763A1 (en) | 2019-05-03 | 2022-07-04 | Nat Univ Singapore | Treatment and prevention of metabolic diseases |
| GB201906291D0 (en) | 2019-05-03 | 2019-06-19 | Singapore Health Serv Pte Ltd | Treatment and prevention of metabolic diseases |
| RU2722398C1 (ru) * | 2019-08-09 | 2020-05-29 | Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства | Моноклональное антитело к БТШ70 |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| EP4247848A4 (en) * | 2020-11-23 | 2025-10-01 | Scout Bio Inc | ANTIGEN-BINDING MOLECULES AND THEIR USES |
| AU2022225064A1 (en) | 2021-02-26 | 2023-08-10 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
| US20250092126A1 (en) | 2021-07-26 | 2025-03-20 | Boehringer Ingelheim International Gmbh | Treatment and prevention of alcoholic liver disease |
| JP2024532620A (ja) | 2021-08-30 | 2024-09-05 | ラッセン・セラピューティクス１・インコーポレイテッド | 抗ＩＬ－１１Ｒα抗体 |
| CN113735975B (zh) * | 2021-09-07 | 2022-08-12 | 广东东阳光药业有限公司 | 一种抗il-11r抗体及其应用 |
| WO2023111196A1 (en) | 2021-12-16 | 2023-06-22 | Singapore Health Services Pte. Ltd. | Treatment and prevention of glomerular disease |
| WO2023143590A1 (zh) * | 2022-01-29 | 2023-08-03 | 迈威(上海)生物科技股份有限公司 | 采用抗il-11抗体的肿瘤组合疗法 |
| KR20250133727A (ko) * | 2023-01-06 | 2025-09-08 | 라센 테라퓨틱스, 인코포레이티드 | 갑상선 안구 질환을 치료하기 위한 항-IL-11Rα 항체 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69535274T2 (de) | 1994-12-22 | 2007-06-06 | Genetics Institute, LLC, Cambridge | Verwendung eines menschlichen interleukin-11 rezeptors |
| US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
| US5679339A (en) | 1995-06-27 | 1997-10-21 | Keith; James | Method of using IL-11 for treating spondyloarthropies |
| US6126933A (en) | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
| GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| GB9721961D0 (en) | 1997-10-16 | 1997-12-17 | Glaxo Group Ltd | Novel molecules |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| US6953777B2 (en) | 1999-03-11 | 2005-10-11 | Genetics Indtitute LLC | Use of interleukin-11 to prevent immune-mediated cytotoxicity |
| AU5756100A (en) | 1999-06-21 | 2001-01-09 | Genetics Institute Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| GB0021668D0 (en) | 2000-09-04 | 2000-10-18 | Smithkline Beecham Plc | New use |
| BR0314356A (pt) | 2002-09-16 | 2005-07-19 | Wyeth Corp | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas |
| EP1709074A4 (en) | 2003-12-16 | 2008-06-11 | Commw Scient Ind Res Org | CYTOKIN BINDING DOMAINS |
| US20060019890A1 (en) | 2004-01-15 | 2006-01-26 | Kapoun Ann M | Method for treating cardiac remodeling following myocardial injury |
| WO2005098041A2 (en) | 2004-03-26 | 2005-10-20 | University Of Florida Research Foundation, Inc. | Detection and treatment of fibrotic disorders |
| EP1630232B1 (en) | 2004-08-27 | 2008-07-02 | CONARIS research institute AG | Optimized nucleotide sequences encoding sgp130 |
| WO2007067602A1 (en) | 2005-12-06 | 2007-06-14 | Wyeth | Interleukin-11 compositions and methods of use |
| CN100441689C (zh) * | 2006-01-20 | 2008-12-10 | 中国人民解放军第三军医大学 | 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用 |
| JP5191393B2 (ja) | 2006-10-27 | 2013-05-08 | 国立大学法人大阪大学 | インターロイキン１１の心疾患治療薬としての利用 |
| ES2536877T3 (es) | 2007-10-26 | 2015-05-29 | Csl Limited | Muteínas de citocina |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| KR101133769B1 (ko) | 2011-04-18 | 2012-04-09 | 한국생명공학연구원 | 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| SG11201505762XA (en) | 2013-02-07 | 2015-08-28 | Csl Ltd | Il-11r binding proteins and uses thereof |
| CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| CN105497893B (zh) | 2015-12-10 | 2019-02-01 | 黑龙江省科学院高技术研究院 | IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用 |
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| KR20190096390A (ko) | 2016-12-16 | 2019-08-19 | 싱가포르 헬스 서비시즈 피티이 엘티디 | Il-11 항체 |
| RU2016151730A (ru) | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
-
2016
- 2016-12-16 GB GBGB1621439.7A patent/GB201621439D0/en not_active Ceased
-
2017
- 2017-12-15 AU AU2017378107A patent/AU2017378107A1/en not_active Abandoned
- 2017-12-15 CA CA3046848A patent/CA3046848A1/en not_active Abandoned
- 2017-12-15 EP EP17836010.3A patent/EP3555135B1/en active Active
- 2017-12-15 TW TW106144202A patent/TW201829465A/zh unknown
- 2017-12-15 WO PCT/EP2017/083043 patent/WO2018109170A2/en not_active Ceased
- 2017-12-15 MX MX2019007021A patent/MX2019007021A/es unknown
- 2017-12-15 JP JP2019532044A patent/JP7175271B2/ja active Active
- 2017-12-15 KR KR1020197020595A patent/KR20190111924A/ko not_active Ceased
- 2017-12-15 BR BR112019012343A patent/BR112019012343A2/pt not_active IP Right Cessation
- 2017-12-15 US US15/843,212 patent/US20180186872A1/en not_active Abandoned
- 2017-12-15 CN CN201780086784.6A patent/CN110337447B/zh active Active
-
2019
- 2019-12-23 US US16/726,190 patent/US11078269B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018109170A2 (en) | 2018-06-21 |
| CN110337447A (zh) | 2019-10-15 |
| US20200207847A1 (en) | 2020-07-02 |
| EP3555135A2 (en) | 2019-10-23 |
| CN110337447B (zh) | 2023-05-26 |
| US20180186872A1 (en) | 2018-07-05 |
| AU2017378107A1 (en) | 2019-07-25 |
| JP2020513745A (ja) | 2020-05-21 |
| GB201621439D0 (en) | 2017-02-01 |
| US11078269B2 (en) | 2021-08-03 |
| JP7175271B2 (ja) | 2022-11-18 |
| MX2019007021A (es) | 2019-10-21 |
| KR20190111924A (ko) | 2019-10-02 |
| WO2018109170A3 (en) | 2018-08-30 |
| TW201829465A (zh) | 2018-08-16 |
| EP3555135B1 (en) | 2024-04-10 |
| CA3046848A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019012343A2 (pt) | anticorpos il-11ra | |
| BR112019012342A2 (pt) | anticorpos il-11 | |
| CY1122653T1 (el) | Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| IL264142A (en) | Multispecific antibodies against cd40 and cd137 | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| EP3445407A4 (en) | COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| PL3443009T3 (pl) | Przeciwciała i kompozycje anty-tim-3 | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| MX2017015464A (es) | Anticuerpos anti-tau y metodos de uso. | |
| MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| EA202092435A2 (ru) | Моноклональные антитела против bcma | |
| PL3506886T3 (pl) | Wysoko stężone preparaty przeciwciał hamujących masp-2 o niskiej lepkości, zestawy i sposoby | |
| MX2018006767A (es) | Composiciones y metodos para oncologia inmunologica. | |
| CL2017003240A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
| CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| TR201810635T4 (tr) | Anti-jagged1 antikorları ve kullanım yöntemleri. | |
| MX377774B (es) | Formulaciones de proteinas. | |
| MX390725B (es) | Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |